financetom
Business
financetom
/
Business
/
Toymaker Hasbro's turnaround efforts help quarterly sales, profit
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Toymaker Hasbro's turnaround efforts help quarterly sales, profit
Jul 25, 2024 4:06 AM

July 25 (Reuters) - Hasbro ( HAS ) posted a

smaller-than-expected drop in second-quarter sales on Thursday

as steady digital gaming demand offset a slump in toy sales,

while cost-control strategies helped the toymaker beat profit

expectations.

Shares of the company were up 6% in premarket trading as

Hasbro ( HAS ) saw margins grow in the quarter to 21.3% compared with a

15.6% decline in margin a year earlier.

The Nerf toy gun maker's turnaround strategy to limit

expenses and maintain a tight inventory amid an industrywide

slowdown in toy demand has helped boost its performance.

The company's quarterly revenue dropped 18% to $995.3

million, smaller than a 22.02% drop estimated by analysts,

according to LSEG data.

On an adjusted basis, Hasbro ( HAS ) earned $1.22 per share in the

second quarter, compared with estimates of 78 cents.

Hasbro ( HAS ) now expects full-year revenue from its consumer

products segment to be down 7% to 11%, compared with its

February forecast of a 7% to 12% decline.

On Tuesday, Barbie maker Mattel ( MAT ) topped Wall Street

estimates for second-quarter profit, aided by a tight control on

costs even as it posted a surprise drop in sales.

(Reporting by Savyata Mishra in Bengaluru; Editing by Shounak

Dasgupta and Shinjini Ganguli)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Prologis tops quarterly estimates on strong warehouse leasing
Prologis tops quarterly estimates on strong warehouse leasing
Oct 15, 2025
Oct 15 (Reuters) - Warehouse-focused real estate investment trust Prologis ( PLD ) beat Wall Street estimates for third-quarter revenue and funds from operations on Wednesday, helped by robust demand for its storage facilities. The San Francisco, California-based company also raised its 2025 core FFO forecast to a range of $5.78 per share to $5.81 per share, from $5.75 per...
Largo Down More Than 50% In US Premarket As Announces Pricing of Registered Direct Offering and Private Placement, Reliance On Financial Hardship Exemption
Largo Down More Than 50% In US Premarket As Announces Pricing of Registered Direct Offering and Private Placement, Reliance On Financial Hardship Exemption
Oct 15, 2025
09:14 AM EDT, 10/15/2025 (MT Newswires) -- Largo (LGO.TO and NASDAQ: LGO) was at last look down more than 50% and at 52 week lows levels as its entered Wednesday into securities purchase agreements with institutional and accredited investors for the purchase and sale of 14,262,309 common shares of the company at a purchase price of US$1.22 per common share...
Plumas Bancorp beats Q3 EPS estimates despite income drop
Plumas Bancorp beats Q3 EPS estimates despite income drop
Oct 15, 2025
Overview * Plumas Bancorp ( PLBC ) beats analysts' expectations for Q3 EPS despite decline in net income * Company's Q3 results were influenced by Cornerstone acquisition, which increased assets and deposits * Net interest income rose by $6.3 mln in Q3 2025 Outlook * Company expects cost of funds to decrease slightly following recent changes and Fed rate reduction...
Scynexis to Receive $22 Million Resolving Disagreement With GSK Over Phase 3 Mario Study; Shares Rise Pre-Bell
Scynexis to Receive $22 Million Resolving Disagreement With GSK Over Phase 3 Mario Study; Shares Rise Pre-Bell
Oct 15, 2025
09:14 AM EDT, 10/15/2025 (MT Newswires) -- Scynexis ( SCYX ) said Wednesday it will receive a $22 million payment from GSK's (GSK) GlaxoSmithKline Intellectual Property (No. 3) Limited, resolving the disagreement related to the restart of the phase 3 Mario study on invasive candidiasis. As per resolution terms, Scynexis ( SCYX ) will terminate the Mario study and receive...
Copyright 2023-2026 - www.financetom.com All Rights Reserved